[EN] AGONISTS OF GPR40<br/>[FR] AGONISTES DE GPR40
申请人:CONNEXIOS LIFE SCIENCES PVT LTD
公开号:WO2012011125A1
公开(公告)日:2012-01-26
The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are therefore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.
The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. They unexpectedly show superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor related diseases in mammals.
A compound of the formula:
or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes.
一个化学式为的化合物:
或其药用可接受的盐,以及一种治疗糖尿病的药物组合物和方法。
[EN] SPIROPIPERIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF FOR TREATING DIABETES<br/>[FR] COMPOSÉS DE SPIROPIPÉRIDINE ET SON UTILISATION PHARMACEUTIQUE POUR LE TRAITEMENT DU DIABÈTE
申请人:LILLY CO ELI
公开号:WO2011046851A1
公开(公告)日:2011-04-21
A compound of the formula:(I) or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes.
一种化合物的公式:(I)或其药学上可接受的盐以及一种治疗糖尿病的药物组合物和方法。
Alkoxyphenylpropanoic Acid Derivatives
申请人:Yasuma Tsuneo
公开号:US20070213364A1
公开(公告)日:2007-09-13
The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula:
wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.